Table 4.
Univariate analysis (positron emission tomography).
| OS | PFS | |||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| B Symptoms (yes vs. no) | 0.257 (0.042–1.562) | 0.140 | 0.213 (0.047–0.967) | 0.045 ∗ |
| SUVmax (≥3.7173 vs. <3.7173) | 34.057 (0.009–127920.296) | 0.401 | 33.806 (0.031–36395.638) | 0.323 |
| MTV (≥66.5 vs. <66.5) | 12.972 (1.448–116.210) | 0.022 ∗ | 8.049 (1.558–41.576) | 0.013 ∗ |
| Histogram based | ||||
|
| ||||
| Kurtosis (≥2.9179 vs. <2.9179) | 13.090 (1.442–118.819) | 0.022 ∗ | 4.293 (0.945–19.509) | 0.059 |
| Shape based | ||||
|
| ||||
| Volume (≥44.8928 vs. <44.8928) | 10.139 (1.131–90.883) | 0.038 ∗ | 6.426 (1.245–33.166) | 0.026 ∗ |
| Compacity (≥1.7565 vs. <1.7565) | 116.242 (0.060–226261.65) | 0.218 | 9.662 (1.161–80.383) | 0.036 ∗ |
| GLRLM | ||||
|
| ||||
| GLNU (≥178.7649 vs. <178.764) | 10.968 (1.814–66.311) | 0.009 ∗ | 14.642 (2.661–80.549) | 0.002 ∗ |
| RLNU (≥257.1264 vs. <257.126) | 99.553 (0.060–164129.050) | 0.224 | 8.487 (1.021–70.553) | 0.048 ∗ |
|
| ||||
| NGLDM | ||||
| Coarseness (≥0.0069 vs. <0.0069) | 0.099 (0.011–0.884) | 0.038 ∗ | 0.156 (0.030–0.804) | 0.026 ∗ |
GLRLM, gray-level run length matrix; GLNU, gray-level nonuniformity; RLNU, run length nonuniformity; NGLDM, neighborhood gray-level difference matrix; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; LDH, lactate dehydrogenase; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. Asterisk (∗) indicates significance with a p value of <0.05 (shown in bold).